A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutationsInvivoscribe Marketing2021-02-11T23:49:39+00:00August 25th, 2018|2018 Publications, Featured Publications, Publications| Read more
Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALLInvivoscribe Marketing2021-02-11T23:54:51+00:00August 22nd, 2018|2018 Publications, Featured Publications, Publications| Read more